• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lung Tissue Injury as an Atypical Response to Nivolumab in Non-Small Cell Lung Cancer.

作者信息

Rampinelli Cristiano, Spitaleri Gianluca, Passaro Antonio, Pochesci Alessia, Ancona Eleonora, De Marinis Filippo

机构信息

1 Division of Radiology and.

2 Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy; and.

出版信息

Am J Respir Crit Care Med. 2017 Nov 15;196(10):1349-1350. doi: 10.1164/rccm.201705-0875IM.

DOI:10.1164/rccm.201705-0875IM
PMID:28910131
Abstract
摘要

相似文献

1
Lung Tissue Injury as an Atypical Response to Nivolumab in Non-Small Cell Lung Cancer.肺组织损伤作为非小细胞肺癌中对纳武单抗的一种非典型反应。
Am J Respir Crit Care Med. 2017 Nov 15;196(10):1349-1350. doi: 10.1164/rccm.201705-0875IM.
2
Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer.一例转移性非小细胞肺癌患者中出现的晚期发生的nivolumab诱导的隐源性机化性肺炎，酷似肺部进展。
Eur J Cancer. 2017 Nov;85:155-157. doi: 10.1016/j.ejca.2017.07.049. Epub 2017 Sep 13.
3
Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient.一名非鳞状转移性非小细胞肺癌患者对纳武单抗的持久反应及免疫相关不良事件
J Thorac Oncol. 2017 May;12(5):e51-e55. doi: 10.1016/j.jtho.2016.12.027.
4
Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient With Advanced Non-Small Cell Lung Cancer: A Case Report.
Ann Intern Med. 2016 Dec 20;165(12):894-895. doi: 10.7326/L16-0137.
5
Nivolumab-associated nausea and vomiting as an immune adverse event.纳武利尤单抗相关的恶心和呕吐作为一种免疫不良事件。
Eur J Cancer. 2017 Oct;84:367-369. doi: 10.1016/j.ejca.2017.07.029. Epub 2017 Aug 18.
6
Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer.纳武单抗诱导的晚期肺癌患者的银屑病和银屑病关节炎。
Rheumatology (Oxford). 2016 Nov;55(11):2087-2089. doi: 10.1093/rheumatology/kew281. Epub 2016 Jul 19.
7
[Psoriasis and Psoriatic Arthritis Induced by Nivolumab in a Patient with Advanced Non-Small-Cell Lung Cancer].[纳武单抗诱发晚期非小细胞肺癌患者的银屑病和银屑病关节炎]
Gan To Kagaku Ryoho. 2017 Sep;44(9):787-789.
8
Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases.在体能状态差或有脑转移的非小细胞肺癌患者中，与纳武单抗相关的原发性疾病的严重加重或表现。
Ann Oncol. 2016 Jul;27(7):1354-6. doi: 10.1093/annonc/mdw148. Epub 2016 Mar 31.
9
Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer.纳武利尤单抗治疗非小细胞肺癌患者诱发重症肌无力
Muscle Nerve. 2016 Sep;54(3):507. doi: 10.1002/mus.25163. Epub 2016 May 30.
10
Nivolumab: a review in advanced squamous non-small cell lung cancer.纳武利尤单抗：晚期鳞状非小细胞肺癌的研究进展。
Drugs. 2015 Nov;75(16):1925-34. doi: 10.1007/s40265-015-0492-9.

引用本文的文献

1
Successful Chemotherapy for Diffuse Cystic Lung Metastases during Targeted Therapy with Osimertinib in a Patient with Non-Small-Cell Lung Cancer: A Literature Review and a Rare Case Report.奥希替尼靶向治疗期间成功化疗非小细胞肺癌患者弥漫性囊性肺转移：文献综述及罕见病例报告
Case Rep Oncol. 2023 Nov 16;16(1):1409-1414. doi: 10.1159/000534711. eCollection 2023 Jan-Dec.
2
Diffuse Cystic Metastases in the Lung after Nivolumab Treatment in a Patient with Non-Small Cell Lung Cancer: A Case Report.纳武单抗治疗非小细胞肺癌患者后肺部弥漫性囊性转移：一例报告
Case Rep Oncol. 2021 Feb 18;14(1):34-38. doi: 10.1159/000513426. eCollection 2021 Jan-Apr.
3
Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab.
免疫检查点抑制剂相关性肺毒性：聚焦纳武利尤单抗。
South Med J. 2020 Nov;113(11):600-605. doi: 10.14423/SMJ.0000000000001166.
4
Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer.非小细胞肺癌免疫检查点抑制后囊性空气腔肺病变的演变。
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2019-000502.